News & Updates

Medical nutrition therapy a boon for adults with prediabetes

Medical nutrition therapy (MNT) provided by a dietitian results in improved glycaemic outcomes, anthropometrics, blood pressure, and most lipid levels in prediabetic adults, according to a systematic review and meta-analysis.

Sugar, except from fruits and veggies, ups risk of CHD

Consumption of total sugar, total glucose equivalents (TGE), added sugar, and fructose from added sugar and juice appears to increase the risk of coronary heart disease (CHD), reveals a study. However, intake of total fructose equivalents (TFE) and fructose from fruits and vegetables does not.

Binge eating, less self-monitoring lead to regain in successful weight losers

Overeating in response to internal and external food cues as well as declines in self-monitoring and body image contribute to weight regain in successful weight losers in a weight-management program, reports a recent study.

Original New Drug Application Approvals by US FDA (16-31 October 2023)

New drug applications approved by US FDA as of 16-31 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Selpercatinib superior to standard MKIs for rare thyroid cancer

Selpercatinib, a highly selective and potent RET inhibitor, trumped two multikinase inhibitors (MKIs) – cabozantinib and vandetanib – for the treatment of advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer (MTC) in the first-line (1L) setting, according to the interim analysis results of the phase III LIBRETTO-531 trial.

American College of Cardiology International Conferences Cardiovascular disease Dyslipidemia management Dyslipidemia

Diet-based weight loss improves biomarkers of endothelial function

Weight loss induced by diet appears to improve biomarkers of endothelial function, according to a study. This intervention suggests a potential strategy to lower the risk of atherosclerosis.

Semaglutide benefits held up for 3 years

Once weekly treatment with the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide significantly reduced HbA_1c level and body weight in a large cohort of adults with type 2 diabetes (T2D) in a real-world study from Israel.